TITLE

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

AUTHOR(S)
Harrison, T. W.; Wisniewski, A.; Honour, J.; Tattersfield, A. B.
PUB. DATE
March 2001
SOURCE
Thorax;Mar2001, Vol. 56 Issue 3, p186
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background-The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fiuticasone propionate and budesonide have been compared in this way the results have been inconsistent. To determine whether this is because of the subjects studied or the sensitivity of the systemic marker used, we have compared the effects of fluticasone propionate and budesonide in healthy and asthmatic subjects and investigated the effect of treatment on three systemic markers. Methods-Forty SIX healthy subjects were randomised to receive inhaled fluticasone propionate 1500 μg/day (via an Accuhaler), budesonide 1600 μg/day (via a Turbuhaler), or placebo; 31 subjects with moderately severe asthma were randomised to receive the same doses of fluticasone propionate or budesonide but not placebo. Systemic effects in healthy and asthmatic subjects were compared after 7 days. Treatment was continued for another 21 days in the subjects with asthma when systemic effects and asthma control were assessed. Results-At baseline healthy subjects had higher urinary levels of total cortisol metabolites (TCM) than subjects with asthma. After 7 days of treatment with fluticasone propionate urinary TCM levels in the healthy subjects were significantly lower than in the subjects with asthma (mean difference between groups 1663 μg/day, 95% CI 328 to 2938). This was not the case with budesonide, however, where urinary TCM levels in the healthy subjects remained above those in the asthmatic subjects (mean difference between groups 1210 μg/day, 95% CI -484 to 2904). Urinary TCM levels were considerably more sensitive to the effects of inhaled corticosteroids than morning serum cortisol or osteocalcin concentrations. Only budesonide reduced the serum level of osteocalcin.
ACCESSION #
12915607

 

Related Articles

  • Mild persistent asthma and inhaled corticosteroids: is daily therapy really necessary? Bauchner, Howard // Archives of Disease in Childhood;Oct2005, Vol. 90 Issue 10, p1094 

    This article cites a study on the treatment of mild persistent asthma, which was published in the May 6, 2005 issue of the "Journal Watch Pediatrics and Adolescent Medicine." In this double-blind trial, researchers randomized 225 adults with mild persistent asthma to receive twice-daily inhaled...

  • Analysis. Summerton, Nick // Update;5/19/2005, Vol. 70 Issue 5, p26 

    This article presents a study to find out whether intermittent as-needed corticosteroid treatment for mild persistent asthma equivalent to regular daily treatment. Treatment with daily or intermittent corticosteroid therapy in a six-centre randomised controlled trial was conducted. After...

  • Inhaled cortico-steroids and COPD exacerbations.  // Infectious Disease Alert;Apr2010 Primary Care, p8 

    The article discusses research done by R. Agarwal and colleagues on inhaled corticosteroids versus placebo for preventing chronic obstructive pulmonary disease (COPD) exacerbations, published in a 2010 issue of "Chest."

  • Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. South, Mike // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p23 

    This article focuses on a study that deals with an early intervention with budesonide in mild persistent asthma. A randomized, double-blind clinical trial in 7241 patients in 32 countries was conducted to assess the effects of budesonide in patients who had mild persistent asthma for less than 2...

  • Safety of Inhaled Budesonide. Christensson, Camilla; Thorén, Anders; Lindberg, Bengt // Drug Safety;2008, Vol. 31 Issue 11, p965 

    Inhaled corticosteroid (ICS) therapy is central to the long-term management of asthma and is extensively used in the management of chronic obstructive pulmonary disease (COPD). While administration via inhalation limits systemic exposure compared with oral or injected corticosteroids and,...

  • Daily asthma drugs not essential. Baines, Emma // GP: General Practitioner;4/15/2005, p2 

    The article informs that mild asthma may be controlled as effectively by short, intermittent courses of inhaled corticosteroids as by daily treatment. The study included 225 adults with persistent, mild asthma who did not smoke. Their FEV1 was at least 70 per cent of the predicted value and they...

  • Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Busse, William W.; Bleecker, Eugene R.; Bateman, Eric D.; Lötvall, Jan; Forth, Richard; Davis, Angela M.; Jacques, Loretta; Haumann, Brett; Woodcock, Ashley // Thorax;Jan2012, Vol. 67 Issue 1, p35 

    Background Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β2 agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. Objectives To determine the...

  • Long-acting beta2-agonists in asthma: not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Inhaled corticosteroids and COPD exacerbations.  // Clinical Cardiology Alert;Apr2010 Primary Care Supplement, Vol. 15 Issue 4, p8 

    The article discusses research on the effectiveness of inhaled corticosteriods compared with placebo in preventing chronic obstructive pulmonary disease (COPD) exacerbations by R. Agarwal and colleagues published in a 2010 issue of "Chest."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics